Chemotherapy with alvenor for rectal cancer with high YWHAB
Part of Cancer, Digestive system clinical trials.
This trial tests adding the drug alvenor to standard chemotherapy before surgery for rectal cancer patients whose tumors have high levels of a protein called YWHAB. The goal is to see if this combination can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (a type of rectal cancer) that has not spread to other parts of the body.
- Your tumor has high levels of the YWHAB protein (a lab test will check this).
- You have not had any previous chemotherapy or other cancer treatments for your rectal cancer.
- You are between 18 and 75 years old and in good overall health (able to perform daily activities).
- You have adequate kidney, liver, and blood cell function (confirmed by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This trial tests a combination of several chemotherapy drugs plus a targeted agent (bevacizumab) to shrink locally advanced rectal cancer, with the goal of avoiding surgery and keeping your rectum intact. It's designed for patients who wish to try this organ-preserving approach.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.